{
    "clinical_study": {
        "@rank": "88976", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study will evaluate the efficacy and safety of first-line\n      Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age\n      groups (<60, 60-69, 70-79, >80 years) in patients with inoperable advanced, metastatic or\n      recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months\n      from the start of first-line therapy."
        }, 
        "brief_title": "AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly\n             non-squamous adenocarcinoma non-small cell lung cancer\n\n        Exclusion Criteria:\n\n          -  Contraindications to Avastin treatment according to the Summary of Product\n             Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with inoperable advanced, metastatic or recurrent predominantly non-squamous\n        adenocarcinoma non-small cell lung cancer"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827852", 
            "org_study_id": "ML28306"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leipzig", 
                    "country": "Germany", 
                    "zip": "04103"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28306 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: BfArm (Federal Institute for Drugs and Medical Devices)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)", 
            "safety_issue": "No", 
            "time_frame": "approximately 4.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }, 
            {
                "measure": "Clinical/demographic patient characteristics at initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }, 
            {
                "measure": "Avastin treatment schedule in routine clinical practice (dosage/duration)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Concomitant anti-neoplastic therapy (dosage/duration)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events in 4 different age groups (<60, 60-69, 70-79, >/=80 years)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}